韓国のFTCはCelltrionに309,900ドルの罰金を科しました 提携会社に不当な利益を与えていたからです South Korea's FTC fined Celltrion $309,900 for favoring its affiliate with unfair benefits.

韓国のFTCは,不正なビジネス慣行のためにバイオ医薬品会社Celltrionに309,900ドルの罰金を科し,その関連会社Celltrion Healthcareを,免除料と無料の商標で優遇し,その不当に 873,000ドルの利益を提供した. South Korea's FTC fined biopharmaceutical firm Celltrion $309,900 for unfair business practices, including favoring its affiliate, Celltrion Healthcare, with waived fees and free trademarks, which provided undue benefits valued at $873,000. FTCは,その関係者の関与に関する利益と不確実性から,議長を検察官に紹介しないことを決めた. The FTC decided not to refer the chairman to prosecutors due to the benefit amount and uncertainty over his involvement. 四半期の売上高にかかわらず,セルトリオンの第三四半期の純収入は62%減少した. Despite high quarterly sales, Celltrion's third-quarter net income dropped 62%.